RxDoctor Payments Data

Adnan Elhammali

Radiation Oncology · Gainesville, GANPI 1366823064

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by GT Medical Technologies, Inc at 24.8% of the total. Reporting peaked in 2023 at $471 and has fallen 72.2% since, to $131 in 2025.

$1,056in general payments, 2019–2025

Across 36 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GT Medical Technologies, Inc$262
  • Sumitomo Pharma America, Inc.$121
  • Boston Scientific$87
  • Novocure Inc.$84
  • Pfizer$75
  • Johnson & Johnson$70
  • plus $357 from 12 others

What the payments were for

  • Food & beverage$1,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,056 in reported general payments places this provider in the 65th percentile of 165 radiation oncology providers in Georgia.

See all radiation oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$306,493
Medicare patients
291
Services billed
3,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix64$171,548
Tamsulosin Hcl111$988
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$777
Dexamethasone24$364
Silver Sulfadiazine11$255
Morphine Sulfate ErMorphine Sulfate17$191
Levetiracetam17$162
Oxybutynin Chloride ErOxybutynin Chloride20$160
Oxybutynin Chloride11$118
Oxycodone Hcl17$83
Lorazepam11$5

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$121$171,54864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 radiation oncology providers in Georgia.

Other radiation oncology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →